Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 1/2018

01-04-2018 | Original Article

Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes

Authors: A. Aragón-Herrera, S. Feijóo-Bandín, D. Rodríguez-Penas, E. Roselló-Lletí, M. Portolés, M. Rivera, M. Bigazzi, D. Bani, O. Gualillo, J. R. González-Juanatey, F. Lago

Published in: Endocrine | Issue 1/2018

Login to get access

Abstract

Purpose

Many evidences show that the hormone relaxin plays a pivotal role in the physiology and pathology of the cardiovascular system. This pleiotropic hormone exerts regulatory functions through specific receptors in cardiovascular tissues: in experimental animal models it was shown to induce coronary vasodilation, prevent cardiac damage induced by ischemia/reperfusion and revert cardiac hypertrophy and fibrosis. A tight relationship between this hormone and important metabolic pathways has been suggested, but it is at present unknown if relaxin could regulate cardiac metabolism. Our aim was to study the possible effects of relaxin on cardiomyocyte metabolism.

Methods

Neonatal rat cardiomyocytes were treated with relaxin and (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assays (MTT) were performed to assess metabolic activity; while 2-deoxy-D-[3H] glucose and BODIPY-labelled fatty acid incorporations were analyzed to measure glucose and fatty acid uptakes, and western blot was utilized to study the intracellular signaling pathways activated by the hormone.

Results

We observed that relaxin at 10 ng/ml was able to increase the level of metabolic activity of cultured neonatal rat cardiomyocytes; the rate of 2-deoxy-D-[3H]glucose incorporation demonstrated that relaxin also induced an increase in glucose uptake. First evidence is also offered that relaxin can activate the master energy sensor and regulator AMPK in cardiomyocytes. Moreover, the treatment of cardiomyocytes with relaxin also induced dose-dependent increases in ERK1/2, AKT, and AS160 phosphorylation. That raise in AS160 phosphorylation induced by relaxin was prevented by the pretreatment with AMPK and AKT pathways inhibitors, indicating that both molecules play important roles in the relaxin effects reported.

Conclusion

Relaxin can regulate cardiomyocyte metabolism and activate AMPK, the central sensor of energy status that maintains cellular energy homeostasis, and also ERK and AKT, two molecular sensing nodes that coordinate dynamic responses of the cell’s metabolic responses.
Literature
1.
R.A. Bathgate, M.L. Halls, E.T. van der Westhuizen, G.E. Callander, M. Kocan, R.J. Summers, Relaxin family peptides and their receptors. Physiol. Rev. 93, 405–480 (2013)CrossRefPubMed
2.
D. Bani, A. Pini, S.K. Yue, Relaxin, insulin and diabetes: an intriguing connection. Curr. Diabetes Rev. 8, 329–335 (2012)CrossRefPubMed
3.
J.R. Teerlink, G. Cotter, B.A. Davison, G.M. Felker, G. Filippatos, B.H. Greenberg et al., RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381, 29–39 (2013)CrossRefPubMed
4.
J.R. Teerlink, A.A. Voors, P. Ponikowski, P.S. Pang, B.H. Greenberg, G. Filippatos et al., Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. Eur. J. Heart Fail. 19, 800–809 (2017)CrossRefPubMedPubMedCentral
5.
S.L. Teichman, E. Unemori, J.R. Teerlink, G. Cotter, M. Metra, Relaxin: review of biology and potential role in treating heart failure. Curr. Heart Fail. Rep. 7, 75–82 (2010)CrossRefPubMedPubMedCentral
6.
R.K. Ghosh, K. Banerjee, R. Tummala, S. Ball, K. Ravakhah, A. Gupta, Serelaxin in acute heart failure: most recent update on clinical and preclinical evidence. Cardiovasc. Ther. 35, 55–63 (2017)CrossRefPubMed
7.
N. Sato, C.S. Lam, J.R. Teerlink, B.H. Greenberg, H. Tsutsui, B.H. Oh et al., Evaluating the efficacy, safety, and tolerability of serelaxin when added to standard therapy in Asian patients with acute heart failure: design and rationale of RELAX-AHF-ASIA Trial. J. Card. Fail. 23, 63–71 (2017)CrossRefPubMed
8.
S. Singh, R.L. Simpson, R.G. Bennett, Relaxin activates peroxisome proliferator-activated receptor γ (PPARγ) through a pathway involving PPARγ coactivator 1α (PGC1α). J. Biol. Chem. 290, 950–959 (2015)CrossRefPubMed
9.
J.S. Bonner, L. Lantier, K.M. Hocking, L. Kang, M. Owolabi, F.D. James et al., Relaxin treatment reverses insulin resistance in mice fed a high-fat diet. Diabetes 62, 3251–3260 (2013)CrossRefPubMedPubMedCentral
10.
B. Szepietowska, M. Gorska, M. Szelachowska, Plasma relaxin concentration is related to beta-cell function and insulin sensitivity in women with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 79, e1–e3 (2008)CrossRefPubMed
11.
X. Zhang, M. Zhu, M. Zhao, W. Chen, Y. Fu, Y. Liu et al., The plasma levels of relaxin-2 and relaxin-3 in patients with diabetes. Clin. Biochem. 46, 1713–1716 (2013)CrossRefPubMed
12.
M.H. Ghattas, E.T. Mehanna, N.M. Mesbah, D.M. Abo-Elmatty, Relaxin-3 is associated with metabolic syndrome and its component traits in women. Clin. Biochem. 46, 45–48 (2013)CrossRefPubMed
13.
B.M. McGowan, J.S. Minnion, K.G. Murphy, N.E. White, D. Roy, S.A. Stanley et al., Central and peripheral administration of human relaxin-2 to adult male rats inhibits food intake. Diabetes Obes. Metab. 12, 1090–1096 (2010)CrossRefPubMed
14.
C. Lenglos, J. Calvez, E. Timofeeva, Sex-specific effects of relaxin-3 on food intake and brain expression of corticotropin-releasing factor in rats. Endocrinology 156, 523–533 (2015)CrossRefPubMed
15.
C. Lenglos, A. Mitra, G. Guèvremont, E. Timofeeva, Regulation of expression of relaxin-3 and its receptor RXFP3 in the brain of diet-induced obese rats. Neuropeptides 48, 119–132 (2014)CrossRefPubMed
16.
H. Yamamoto, H. Shimokawa, T. Haga, Y. Fukui, K. Iguchi, K. Unno et al., The expression of relaxin-3 in adipose tissue and its effects on adipogenesis. Protein Pept. Lett. 21, 517–522 (2014)CrossRefPubMed
17.
18.
J.R. González-Juanatey, M.J. Iglesias, C. Alcaide, R. Piñeiro, F. Lago, Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of alpha1-adrenergic blockade. Circulation 107, 127–131 (2003)CrossRefPubMed
19.
R. Piñeiro, M.J. Iglesias, R. Gallego, K. Raghay, S. Eiras, J. Rubio et al., Adiponectin is synthesized and secreted by human and murine cardiomyocytes. FEBS Lett. 579, 5163–5169 (2005)CrossRefPubMed
20.
P.V. Lear, M.J. Iglesias, S. Feijóo-Bandín, D. Rodríguez-Penas, A. Mosquera-Leal, V. García-Rúa et al., Des-acyl ghrelin has specific binding sites and different metabolic effects from ghrelin in cardiomyocytes. Endocrinology 151, 3286–3298 (2010)CrossRefPubMed
21.
J. Pu, G. Peng, L. Li, H. Na, Y. Liu, P. Liu, Palmitic acid acutely stimulates glucose uptake via activation of Akt and ERK1/2 in skeletal muscle cells. J. Lipid Res. 52, 1319–1327 (2011)CrossRefPubMedPubMedCentral
22.
L.K.M. Steinbusch, R.W. Schwenk, D.M. Ouwens, M. Diamant, J.F.C. Glatz, J.J.F.P. Luiken, Subcellular trafficking of the substrate transporters GLUT4 and CD36 in cardiomyocytes. Cell Mol. Life Sci. 68, 2525–2538 (2011)CrossRefPubMedPubMedCentral
23.
C.T. Lee, J.R. Ussher, A. Mohammad, A. Lam, G.D. Lopaschuk, 5′-AMP-activated protein kinase increases glucose uptake independent of GLUT4 translocation in cardiac myocytes. Can. J. Physiol. Pharmacol. 92, 307–314 (2014)CrossRefPubMed
24.
S.R. Hargett, N.N. Walker, S.R. Keller, Rab GAPs AS160 and Tbc1d1 play nonredundant roles in the regulation of glucose and energy homeostasis in mice. Am. J. Physiol. Endocrino Metab. 310, E276–E288 (2016)CrossRef
25.
J. Nonhoff, M. Ricke-Hoch, M. Mueller, B. Stapel, T. Pfeffer, M. Kasten et al., Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy. Cardiovasc. Res. 113, 598–608 (2017)PubMedPubMedCentral
26.
E. Unemori, Serelaxin in clinical development: past, present and future. Br. J. Pharmacol. 174, 921–932 (2017)CrossRefPubMed
27.
A.M. Perna, E. Masini, S. Nistri, T. Bani Sacchi, M. Bigazzi, D. Bani, Human recombinant relaxin reduces heart injury and improves ventricular performance in a swine model of acute myocardial infarction. Ann. N. Y. Acad. Sci. 1041, 431–433 (2005)CrossRefPubMed
28.
A.M. Perna, E. Masini, S. Nistri, V. Briganti, L. Chiappini, P. Stefano et al., Novel drug development opportunity for relaxin in acute myocardial infarction: evidences from a swine model. FASEB J. 19, 1525–1527 (2005)CrossRefPubMed
29.
C.H. Leo, M. Jelinic, H.C. Parkington, M. Tare, L.J. Parry, Acute intravenous injection of serelaxin (recombinant human relaxin-2) causes rapid and sustained bradykinin-mediated vasorelaxation. J. Am. Heart Assoc. 3, e000493 (2014)CrossRefPubMedPubMedCentral
30.
T. Dschietzig, A. Brecht, C. Bartsch, G. Baumann, K. Stangl, K. Alexiou, Relaxin improves TNF-α-induced endothelial dysfunction: the role of glucocorticoid receptor and phosphatidylinositol 3-kinase signalling. Cardiovasc. Res. 95, 97–107 (2012)CrossRefPubMed
31.
H.H. Ng, C.H. Leo, L.J. Parry, Serelaxin (recombinant human relaxin-2) prevents high glucose-induced endothelial dysfunction by meliorating prostacyclin production in the mouse aorta. Pharmacol. Res. 107, 220–228 (2016)CrossRefPubMed
32.
V. Tiyerili, T. Beiert, H. Schatten, B. Camara, J. Jehle, J.W. Schrickel et al., Anti-atherosclerotic effects of serelaxin in apolipoprotein E-deficient mice. Atherosclerosis 251, 430–437 (2016)CrossRefPubMed
33.
C.S. Samuel, E.N. Unemori, I. Mookerjee, R.A. Bathgate, S.L. Layfield, J. Mak et al., Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 145, 4125–4133 (2004)CrossRefPubMed
34.
D. Bani, S. Nistri, L. Formigli, E. Meacci, F. Francini, S. Zecchi-Orlandini, Prominent role of relaxin in improving postinfarction heart remodeling. Ann. N. Y. Acad. Sci. 1160, 269–277 (2009)CrossRefPubMed
35.
A. Frati, B. Ricci, F. Pierucci, S. Nistri, D. Bani, E. Meacci, Role of sphingosine kinase/S1P axis in ECM remodeling of cardiac cells elicited by relaxin. Mol. Endocrinol. 29, 53–67 (2015)CrossRefPubMed
36.
J. Valle Raleigh, A.G. Mauro, T. Devarakonda, C. Marchetti, J. He, E. Kim et al., Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism. Cardiovasc. Res. 113, 609–619 (2017)PubMed
37.
A. Parikh, D. Patel, C.F. McTiernan, W. Xiang, J. Haney, L. Yang et al., Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts. Circ. Res. 113, 313–321 (2013)CrossRefPubMedPubMedCentral
38.
B.L. Henry, B. Gabris, Q. Li, B. Martin, M. Giannini, A. Parikh, D. Patel et al., Relaxin suppresses atrial fibrillation in aged rats by reversing fibrosis and upregulating Na + channels. Heart Rhythm. 13, 983–991 (2016)CrossRefPubMed
39.
L. Formigli, F. Francini, L. Chiappini, S. Zecchi-Orlandini, D. Bani, Relaxin favors the morphofunctional integration between skeletal myoblasts and adult cardiomyocytes in coculture. Ann. N. Y. Acad. Sci. 1041, 444–445 (2005)CrossRefPubMed
40.
X.L. Moore, S.L. Tan, C.Y. Lo, L. Fang, Y.D. Su, X.M. Gao et al., Relaxin antagonizes hypertrophy and apoptosis in neonatal rat cardiomyocytes. Endocrinology 148, 1582–1589 (2007)CrossRefPubMed
41.
L. Formigli, F. Francini, S. Nistri, M. Margheri, G. Luciani, F. Naro et al., Skeletal myoblasts overexpressing relaxin improve differentiation and communication of primary murine cardiomyocyte cell cultures. J. Mol. Cell Cardiol. 47, 335–345 (2009)CrossRefPubMed
42.
S. Nistri, A. Pini, C. Sassoli, R. Squecco, F. Francini, L. Formigli et al., Relaxin promotes growth and maturation of mouse neonatal cardiomyocytes in vitro: clues for cardiac regeneration. J. Cell Mol. Med. 16, 507–519 (2012)CrossRefPubMedPubMedCentral
43.
C. Sassoli, F. Chellini, A. Pini, A. Tani, S. Nistri, D. Nosi et al., Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-β/Smad3 signaling. PLoS One 8, e63896 (2013)CrossRefPubMedPubMedCentral
44.
G. Boccalini, C. Sassoli, L. Formigli, D. Bani, S. Nistri, Relaxin protects cardiac muscle cells from hypoxia/reoxygenation injury: involvement of the Notch-1 pathway. FASEB J. 29, 239–249 (2015)CrossRefPubMed
45.
T. Dschietzig, C. Richter, C. Bartsch, M. Laule, F.P. Armbruster, G. Baumann et al., The pregnancy hormone relaxin is a player in human heart failure. FASEB J. 15, 2187–2195 (2001)CrossRefPubMed
46.
X. Zhang, X. Ma, M. Zhao, B. Zhang, J. Chi, W. Liu et al., H2 and H3 relaxin inhibit high glucose-induced apoptosis in neonatal rat ventricular myocytes. Biochimie 108, 59–67 (2015)CrossRefPubMed
47.
A. Pini, G. Boccalini, M.C. Baccari, M. Becatti, R. Garella, C. Fiorillo et al., Protection from cigarette smoke-induced vascular injury by recombinant human relaxin-2 (serelaxin). J. Cell Mol. Med. 20, 891–902 (2016)CrossRefPubMedPubMedCentral
48.
L.H. Bergeron, J.M. Willcox, F.J. Alibhai, B.J. Connell, T.M. Saleh, B.C. Wilson et al., Relaxin peptide hormones are protective during the early stages of ischemic stroke in male rats. Endocrinology 156, 638–646 (2015)CrossRefPubMed
49.
X. Ma, S. Han, W. Zhang, Y.J. Fan, M.N. Liu, A.Y. Liu et al., Protection of cultured human hepatocytes from hydrogen peroxide-induced apoptosis by relaxin-3. Mol. Med Rep. 11, 1228–1234 (2015)CrossRefPubMed
50.
K. Domińska, T. Ochędalski, K. Kowalska, Z.E. Matysiak-Burzyńska, E. Płuciennik, A.W. Piastowska-Ciesielska, Interaction between angiotensin II and relaxin 2 in the progress of growth and spread of prostate cancer cells. Int. J. Oncol. 48, 2619–2628 (2016)CrossRefPubMed
51.
X.C. Xie, N. Zhao, Q.H. Xu, X. Yang, W.K. Xia, Q. Chen et al., Relaxin attenuates aristolochic acid induced human tubular epithelial cell apoptosis in vitro by activation of the PI3K/Akt signaling pathway. Apoptosis 22, 769–776 (2017)CrossRefPubMed
52.
A. Fukushima, K. Milner, A. Gupta, G.D. Lopaschuk, Myocardial energy substrate metabolism in heart failure: from pathways to therapeutic targets. Curr. Pharm. Des. 21, 3654–3664 (2015)CrossRefPubMed
53.
M. Collino, M. Rogazzo, A. Pini, E. Benetti, A.C. Rosa, F. Chiazza et al., Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injury. J. Cell. Mol. Med. 17, 1494–1505 (2013)CrossRefPubMedPubMedCentral
54.
X.X. Shuai, Y.D. Meng, Y.X. Lu, G.H. Su, X.F. Tao, J. Han et al., Relaxin-2 improves diastolic function of pressure-overloaded rats via phospholamban by activating Akt. Int. J. Cardiol. 218, 305–311 (2016)CrossRefPubMed
55.
H.J. Sun, D. Chen, Y. Han, Y.B. Zhou, J.J. Wang, Q. Chen et al., Relaxin in paraventricular nucleus contributes to sympathetic overdrive and hypertension via PI3K-Akt pathway. Neuropharmacology 103, 247–256 (2016)CrossRefPubMed
56.
O. Ogunleye, B. Campo, D. Herrera, E.D. Post Uiterweer, K.P. Conrad, Relaxin confers cytotrophoblast protection from hypoxia-reoxygenation injury through the phosphatidylinositol 3-kinase-Akt/protein kinase B cell survival pathway. Am. J. Physiol. Regul. Integr. Comp. Physiol. 312, R559–R568 (2017)CrossRefPubMed
57.
X.L. Moore, Y. Su, Y. Fan, Y.Y. Zhang, E.A. Woodcock, A.M. Dart et al., Diverse regulation of cardiac expression of relaxin receptor by α1- and β1-adrenoceptors. Cardiovasc. Drugs Ther. 28, 221–228 (2014)CrossRefPubMed
58.
M.A. Sussman, M. Völkers, K. Fischer, B. Bailey, C.T. Cottage, S. Din et al., Myocardial AKT: the omnipresent nexus. Physiol. Rev. 91, 1023–1070 (2011)CrossRefPubMedPubMedCentral
59.
G.D. Cartee, J.F. Wojtaszewski, Role of AKT substrate of 160 kDa in insulin-stimulated and contraction-stimulated glucose transport. Appl. Physiol. Nutr. Metab. 32, 557–566 (2007)CrossRefPubMed
60.
N. Fujii, N. Jessen, L.J. Goodyear, AMP-activated protein kinase and the regulation of glucose transport. Am. J. Physiol. Endocrinol. Metab. 291, E867–E877 (2006)CrossRefPubMed
61.
I.P. Salt, D.G. Hardie, AMP-activated protein kinase: an ubiquitous signaling pathway with key roles in the cardiovascular system. Circ. Res. 120, 1825–1841 (2017)CrossRefPubMedPubMedCentral
62.
R.R. Russell 3rd, R. Bergeron, G.I. Shulman, L.H. Young, Translocation of myocardial GLUT-4 and increased glucose uptake through activation of AMPK by AICAR. Am. J. Physiol. 277, H643–H649 (1999)PubMed
63.
H.F. Kramer, C.A. Witczak, N. Fujii, N. Jessen, E.B. Taylor, D.E. Arnolds et al., Distinct signals regulate AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse skeletal muscle. Diabetes 55(2), 067–2076 (2006)
64.
A. Ginion, J. Auquier, C.R. Benton, C. Mouton, J.L. Vanoverschelde, L. Hue et al., Inhibition of the mTOR/p70S6K pathway is not involved in the insulin-sensitizing effect of AMPK on cardiac glucose uptake. Am. J. Physiol. Heart Circ. Physiol. 301, H469–H477 (2011)CrossRefPubMed
Metadata
Title
Relaxin activates AMPK-AKT signaling and increases glucose uptake by cultured cardiomyocytes
Authors
A. Aragón-Herrera
S. Feijóo-Bandín
D. Rodríguez-Penas
E. Roselló-Lletí
M. Portolés
M. Rivera
M. Bigazzi
D. Bani
O. Gualillo
J. R. González-Juanatey
F. Lago
Publication date
01-04-2018
Publisher
Springer US
Published in
Endocrine / Issue 1/2018
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-018-1534-3

Other articles of this Issue 1/2018

Endocrine 1/2018 Go to the issue

Original Article

Ambulatory blood pressure monitoring-derived short-term blood pressure variability in primary hyperparathyroidism

Review

The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?

Editorial

Somatostatin and diabetic retinopathy: an evolving story

Letter to the Editor

Reply to letter to the editor “Blood pressure variability in primary hyperparathyroidism: more data needed”

Original Article

MiR-145 improves macrophage-mediated inflammation through targeting Arf6

Letter to the Editor

Blood pressure variability in primary hyperparathyroidism: more data needed
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits